We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look ...

As the body of research grows around the potential promise of psychedelic medications in psychiatry, many questions and challenges remain.  The January issue of the American Journal of Psychiatry ...

NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary ...

Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market ...

A world-first trial has been carried out at the Royal Preston Hospital, which could revolutionise global health policy.

Novartis intrathecal onasemnogene abeparvovec phase III STEER study meets primary endpoint in children and young adults with SMA: Basel Tuesday, December 31, 2024, 11:00 Hrs [IST] ...

The randomised, sham-controlled study assessed the efficacy and safety of the gene therapy in treatment-naïve individuals aged two to less than 18 years who can sit but have never walked independently ...

Curocell launches Limcato, South Koreas first domestic CAR-T cancer therapy Curocell introduces first local CAR-T therapy, ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

If Altimmune can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock. Click ...

The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT) OAV101 IT ...

Hemogenyx Pharmaceuticals Opens First Clinical Site for HG-CT-1 Phase I Trial Patient Recruitment Begins for CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia in Adults ...